FibroBiologics, Inc. Common Stock (FBLG) Stock Ticker
FBLG right now
Market factors today
Unlock the full FBLG picture
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
FBLG stock facts
| Ticker symbol | FBLG |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.9M |
| CEO | Peter O'Heeron |
| Employees | 15 |
| Headquarters | Houston, TX, US |
| IPO date | 2024-02-01 |
| Website | www.fibrobiologics.com |
What you can see for FBLG on Tickr
Live FBLG price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the FBLG report.
Rankings
FAQ
What is the ticker symbol for FibroBiologics, Inc. Common Stock?
The ticker symbol for FibroBiologics, Inc. Common Stock is FBLG, listed on the NASDAQ Capital Market.
What is FBLG?
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage…